- Author: Joseph C Landolfi, DO; Chief Editor: Tarakad S Ramachandran, MBBS, MBA, MPH, FAAN, FACP, FAHA, FRCP, FRCPC, FRS, LRCP, MRCP, MRCS more...
Brainstem gliomas are tumors that occur in the region of the brain between the aqueduct of Sylvius and the fourth ventricle. Brainstem gliomas account for approximately 10-20% of all childhood brain tumors. The incidence in adults is lower than that in children younger than 16 years. See the image below.
Signs and symptoms
Common presenting signs and symptoms include the following:
Difficulty in swallowing
Behavioral changes or seizures in children (rare)
Deterioration of handwriting and speech, in older children
Common clinical findings on physical examination can be summarized as constituting a triad of cranial nerve deficits, long tract signs, and ataxia (of trunk and limbs). Papilledema may be seen. Sixth and seventh cranial nerves are involved commonly. Facial sensory loss and a primary-position, upbeating nystagmus may be seen.
Certain manifestations suggest specific tumor locations, as follows:
Infants and children with failure to thrive – Pontine gliomas
Involvement of cranial nerve III or IV – A mesencephalic component
Hydrocephalus – Tumors in periaqueductal or fourth ventricle outflow locations
Patients with tectal lesions may present with the following:
Headache, nausea, and vomiting
Patients with cervicomedullary lesions may present with the following:
Dysphagia, unsteadiness, nasal speech, vomiting, and weakness
Sensory loss in the face (involvement of the trigeminal nucleus)
Dysphagia and/or dysphonia from lower cranial nerve involvement (commonly IX and X)
Long tract signs
Downbeating nystagmus and oculomyoclonus (medullary involvement)
See Clinical Presentation for more detail.
The workup for brainstem gliomas may include the following:
MRI of the head – Diagnostic test of choice
CT scan – Less accurate than MRI, but appropriate when MRI is not available
CSF examination – Often important for differential diagnosis
Arteriography – Occasionally useful in differentiating vascular lesions, including tumors, from gliomas
Lab studies of blood chemistry and related body fluids are not helpful as a rule. Tissue confirmation is frequently not feasible.
See Workup for more detail.
Treatment of brainstem gliomas may comprise the following:
Focal radiotherapy 
Observation alone may be considered for some adult patients with any of the following:
A tectal lesion
A cervicomedullary lesion
Mild symptoms of long duration
The cornerstone of treatment of brainstem gliomas
Can improve or stabilize the patient's condition
Should be administered to any patient with significant and progressive neurologic symptoms
The conventional dose of radiotherapy ranges from 54-60 Gy, with doses up to 72 Gy given with hyperfractionation
Reported survival rates with radiation therapy are better in patients with exophytic tumors
Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas 
Postradiotherapy adjuvant chemotherapy cannot be recommended
Chemotherapy at relapse may benefit some patients
Chemotherapy may include conventional agents such as temozolomide and carboplatin/vincristine
Antiangiogenesis agents (eg, thalidomide, bevacizumab) have been used with success in supratentorial glioblastomas
If chemotherapy is desired adjuvantly or concurrently with radiotherapy, particularly in the pediatric population, consider entering the patient into a clinical trial
Surgical therapy is performed in conjunction with radiation therapy, chemotherapy, or both. It is not required for diagnosis or treatment of diffuse intrinsic pontine or tectal gliomas; it is most appropriate in the following cases:
Tumors of the cervicomedullary junction
Dorsal exophytic tumors protruding into the fourth ventricle
Enhancing tumors with clear margins that exert a space-occupying effect
Benign tumors (ie, those with slow clinical progression)
Brainstem gliomas are tumors that occur in the region of the brain referred to as the brain stem, which is the area between the aqueduct of Sylvius and the fourth ventricle. Although various systems are used to classify these tumors, the authors have divided brainstem gliomas into 3 distinct anatomic locations—diffuse intrinsic pontine, tectal, and cervicomedullary. Intrinsic pontine gliomas carry a grave prognosis. Longer survival is associated with the tectal and cervicomedullary gliomas. Tumors also are characterized on the basis of site of origin, focality, direction and extent of tumor growth, degree of brainstem enlargement, degree of exophytic growth, and presence or absence of cysts, necrosis, hemorrhage, and hydrocephalus.
These tumors have a predilection to originate from the left side. Most are located in the pons; however, medulla and midbrain may be involved as well. Brainstem gliomas are highly aggressive brain tumors. Anatomic location determines the pathophysiological manifestation of the tumor. With tectal lesions, hydrocephalus may occur as a result of fourth ventricular compression. With pontine and cervicomedullary lesions, cranial nerve or long tract signs are observed commonly.
Histopathologically, brainstem gliomas can range from WHO Grade 1 to 4. Grade 1 is the juvenile pilocytic astrocytoma, Grade 2 is the diffuse astrocytoma, Grade 3 is the anaplastic astrocytoma, and grade 4 is the glioblastoma multiforme. The grading is based on the presence of nuclear atypia, vascular proliferation, mitoses, and necrosis. Typically, the necrosis is seen in Grade 4 (glioblastoma multiforme).
Molecular profiling is now an important part of glioma classification. An IDH1 mutation carries an improved prognosis over the IDH1 wildtype, no matter what the tumor grade. Codeletions of Chromosome 1p and 19q along with an IDH1 mutation indicates an oligodendroglioma in Grade 1-3 gliomas. For pediatric diffuse gliomas, a newly defined entity termed diffuse midline glioma, H3 K27M-mutant is characterized by K27M mutations in the histone H3 gene, a diffuse growth pattern and a midline location. This newly defined entity occurs primarilty in children, but can be seen in adults, and includes tumors previously referred to as diffuse intrinsic pontine glioma (DIPG).
Although biopsy or resection is not typically performed on brainstem gliomas, vascular endothelial growth factor (VEGF) receptors are an important pathway in the invasion and growth of supratentorial glioblastomas by promoting the growth of new blood vessels. Epidermal growth factor receptors (EGFR) are present in 25% of glioblastomas and are important in the growth of these neoplasms as well. The presence of these receptors may aid in the response to various targeted therapies, as is discussed in Medical Care.
Brainstem gliomas have been reported to make up 2.4% of all intracranial tumors in adults and 9.4% of intracranial tumors in children. Brainstem gliomas account for approximately 10-20% of all childhood brain tumors. The incidence in adults is lower than that in children younger than 16 years. A tendency for brainstem gliomas to follow a more indolent course in adults than in children has been noted; in adults, these tumors are more likely to be low grade and remain localized.
Morbidity is due to the location of the space-occupying lesion and compression of surrounding structures; because these structures regulate basic body functions of blood pressure, respiration, and swallowing as well as motor and sensory functions, compression can produce substantial neurological disability.
Sudden death can result from increased intracranial pressure and subsequent cerebral herniation. This may be a consequence either of edema induced by the tumor or of hemorrhage into the neoplasm.
Race-, sex-, and age-related demographics
CNS tumors vary in incidence by age, sex, ethnic group, and country, and also over time. How much of this variation is due to artifactual influences or etiologic differences has been the subject of many debates.
Some reports have suggested a slight male preponderance, whereas others have failed to observe any sex predilection.
Bimodal age distribution has been noted, with a peak incidence in the latter half of the first decade of life and a second peak in the fourth decade. Approximately three fourths of patients are younger than 20 years.
Neoplasms of the brain stem have been identified in children younger than 1 year.
Vesper J, Bölke B, Wille C, Gerber PA, Matuschek C, Peiper M, et al. Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view. Eur J Med Res. 2009 Mar 17. 14(3):93-101. [Medline].
Frappaz D, Schell M, Thiesse P et al. Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic pontine gliomas: Final results of BSG 98 prospective trial. Neuro Oncol. Aug/2008. 10(4):599-607. [Medline].
Frazier JL, Lee J, Thomale UW, Noggle JC, Cohen KJ, Jallo GI. Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr. 2009 Apr. 3(4):259-69. [Medline].
Ueoka DI, Nogueira J, Campos JC, Maranhão Filho P, Ferman S, Lima MA. Brainstem gliomas--retrospective analysis of 86 patients. J Neurol Sci. 2009 Jun 15. 281(1-2):20-3. [Medline].
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun. 131(6):803-20. [Medline].
Grau SJ, Rachinger W, Holtmannspoetter M, Herms J, Tonn JC, Kreth FW. Serial Stereotactic Biopsy of Brainstem Lesions in Adults Improves Diagnostic Accuracy Compared to MRI Only. J Neurol Neurosurg Psychiatry. 2009 Jun 10. [Medline].
Raza S, Donach M. Bevacizumab in adult malignant brainstem gliomas. J Neurooncol. 2009 Jun 9. [Medline].
Kaplan AM, Albright AL, Zimmerman RA, Rorke LB, Li H, Boyett JM, et al. Brainstem gliomas in children. A Children's Cancer Group review of 119 cases. Pediatr Neurosurg. 1996. 24(4):185-92. [Medline].
Squires LA, Allen JC, Abbott R, Epstein FJ. Focal tectal tumors: management and prognosis. Neurology. 1994 May. 44(5):953-6. [Medline].
Grigsby PW, Garcia DM, Simpson JR, et al. Prognostic factors and results of therapy for adult thalamic and brainstem tumors. Cancer. 1989 Jun 1. 63(11):2124-9. [Medline].
Landolfi JC, Thaler HT, DeAngelis LM. Adult brainstem gliomas. Neurology. 1998 Oct. 51(4):1136-9. [Medline].
Hamilton MG, Lauryssen C, Hagen N. Focal midbrain glioma: long term survival in a cohort of 16 patients and the implications for management. Can J Neurol Sci. 1996 Aug. 23(3):204-7. [Medline].
Kesari S, Kim RS, Markos V, Drappatz J, Wen PY, Pruitt AA. Prognostic factors in adult brainstem gliomas: a multicenter, retrospective analysis of 101 cases. J Neurooncol. 2008 Jun. 88(2):175-83. [Medline].
Abbott R, Shiminski-Maher T, Epstein FJ. Intrinsic tumors of the medulla: predicting outcome after surgery. Pediatr Neurosurg. 1996 Jul. 25(1):41-4. [Medline].
Albright AL, Guthkelch AN, Packer RJ, et al. Prognostic factors in pediatric brain-stem gliomas. J Neurosurg. 1986 Dec. 65(6):751-5. [Medline].
Barkovich AJ, Krischer J, Kun LE, et al. Brain stem gliomas: a classification system based on magnetic resonance imaging. Pediatr Neurosurg. 1990-91. 16(2):73-83. [Medline].
Cohen ME, Duffner PK. 2nd ed. Brain Tumors in Children: Principles of Diagnosis and Treatment. New York: Raven Press; 1994.
Cohen ME, Duffner PK, Heffner RR, et al. Prognostic factors in brainstem gliomas. Neurology. 1986 May. 36(5):602-5. [Medline].
Dunkel IJ, O'Malley B, Finlay JL. Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood?. Pediatr Neurosurg. 1996. 24(5):263-6. [Medline].
Edwards MS, Wara WM, Urtasun RC, et al. Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. J Neurosurg. 1989 May. 70(5):691-700. [Medline].
Epstein F, Wisoff J. Intra-axial tumors of the cervicomedullary junction. J Neurosurg. 1987 Oct. 67(4):483-7. [Medline].
Fenichel Gerald M. Clinical Pediatric Neurology: A Signs and Symptoms Approach. 3rd ed. Philadelphia: WB Saunders Company; 1997.
Guiney MJ, Smith JG, Hughes P, et al. Contemporary management of adult and pediatric brain stem gliomas. Int J Radiat Oncol Biol Phys. 1993 Jan 15. 25(2):235-41. [Medline].
Jallo GI, Biser-Rohrbaugh A, Freed D. Brainstem gliomas. Childs Nerv Syst. 2004 Mar. 20(3):143-53. [Medline].
Kaye AH, Laws ER. Brain Tumors. New York: Churchill Livingstone; 1995.
Milstein JM, Geyer JR, Berger MS, Bleyer WA. Favorable prognosis for brainstem gliomas in neurofibromatosis. J Neurooncol. 1989 Nov. 7(4):367-71. [Medline].
Rosenblum RK. Brain stem glioma: two case studies. J Pediatr Oncol Nurs. 2005 Mar-Apr. 22(2):114-8. [Medline].
Tokuriki Y, Handa H, Yamashita J, et al. Brainstem glioma: an analysis of 85 cases. Acta Neurochir (Wien). 1986. 79(2-4):67-73. [Medline].
Walker DA, Liu J, Kieran M, Jabado N, Picton S, Packer R, et al. A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol. 2013 Apr. 15(4):462-8. [Medline]. [Full Text].